Equities Analysts Issue Forecasts for CSTL Q1 Earnings

Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Castle Biosciences in a research note issued to investors on Friday, February 28th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings per share of ($0.57) for the quarter. The consensus estimate for Castle Biosciences' current full-year earnings is $0.44 per share. Leerink Partnrs also issued estimates for Castle Biosciences' Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.36) EPS and FY2027 earnings at ($1.32) EPS.

CSTL has been the topic of several other research reports. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a report on Thursday, January 2nd. Scotiabank raised their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research note on Wednesday, November 6th. Finally, Robert W. Baird upped their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $40.00.

Castle Biosciences Price Performance

Shares of CSTL traded down $0.48 during mid-day trading on Monday, reaching $20.84. The company had a trading volume of 170,286 shares, compared to its average volume of 455,671. The company's 50-day moving average is $26.87 and its 200-day moving average is $29.05. Castle Biosciences has a twelve month low of $16.97 and a twelve month high of $35.84. The company has a market capitalization of $583.75 million, a P/E ratio of 104.98 and a beta of 0.98. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64.

Remove Ads

Insider Activity

In other news, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $28.34, for a total value of $265,375.76. Following the completion of the sale, the insider now directly owns 84,762 shares in the company, valued at approximately $2,402,155.08. This represents a 9.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,799 shares of company stock worth $824,289 in the last 90 days. Corporate insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On Castle Biosciences

A number of large investors have recently bought and sold shares of CSTL. Wellington Management Group LLP bought a new stake in shares of Castle Biosciences in the fourth quarter worth $19,244,000. Point72 Asset Management L.P. increased its stake in Castle Biosciences by 828.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company's stock valued at $14,237,000 after buying an additional 445,415 shares during the last quarter. Millennium Management LLC lifted its position in Castle Biosciences by 290.5% during the 4th quarter. Millennium Management LLC now owns 548,809 shares of the company's stock worth $14,626,000 after buying an additional 408,272 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Castle Biosciences during the 4th quarter worth about $6,639,000. Finally, Captrust Financial Advisors grew its holdings in shares of Castle Biosciences by 2,567.5% in the 4th quarter. Captrust Financial Advisors now owns 215,322 shares of the company's stock valued at $5,738,000 after acquiring an additional 207,250 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.